Apollomics, Inc.
NEWS
Financing will accelerate development of the Company’s cancer immunotherapy and targeted therapy programs
CBT’s c-Met inhibitor and anti-PD1 antibody to be evaluated in combination with Bossan’s EGFR inhibitor
CBT Pharmaceuticals today announced it has been awarded a Small Business Innovation Research (SBIR) Grant from the U.S. Department of Health and Human Services National Cancer Institute (NCI) of the National Institutes of Health (NIH).
CBT Pharmaceuticalstoday announced the initiation of the APOLLO Oncology Clinical Trials Program.
CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced a new global leadership structure and the appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing.
Now in its fourth day, the American Association of Cancer Research (AACR) Annual Meeting 2018 held in Chicago, has had plenty of news, much of it preclinical or early-clinical data.
BioSpace is proud to present its NextGen “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
Based in Santa Clara, California, CBT Pharma was spun out of Crown Bioscience with four development-stage assets in the oncology space.
JOBS
IN THE PRESS